Determination of L-2-oxothiazolidine-4-carboxylic acid (Procysteine) in human plasma by high-performance liquid chromatography. NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Determination of L-2-oxothiazolidine-4-carboxylic acid (Procysteine) in human plasma by high-performance liquid chromatography.

J Chromatogr B Biomed Appl. 1994 Apr 1;654(2):257-62. Unique Identifier : AIDSLINE MED/94319483
Webb LE; Gechman M; Story K; Baxter Healthcare Corporation, Round Lake, IL 60073.

Abstract: A new high-performance liquid chromatographic (HPLC) method has been developed for the determination of the cysteine prodrug, L-2-oxothiazolidine-4-carboxylic acid (Procysteine), in human plasma. Samples were mixed with 5% metaphosphoric acid and the supernatants chromatographed using a reversed-phase analytical column. Procysteine was detected spectrophotometrically at 230 nm and quantitated by comparison with a standard curve of known amounts of Procysteine (20-1000 microM) in plasma. The coefficients of variation for 48.6 microM and 676 microM control pools were 6.5 and 4.0% respectively (n = 46). Deviations from the expected concentrations were less than 2%. The method has been utilized to evaluate the pharmacokinetics of a wide range of oral and intravenous doses.
Keywords: Administration, Oral Chromatography, High Pressure Liquid Chromatography, Ion Exchange Human HIV Infections/BLOOD Indicators and Reagents Injections, Intravenous Quality Control Reference Standards Respiratory Distress Syndrome, Adult/BLOOD Spectrophotometry, Ultraviolet Thiazoles/ADMINISTRATION & DOSAGE/*BLOOD/PHARMACOKINETICS JOURNAL ARTICLE


941130
M94B0734

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .